This article reviews recent dichloromethane news, focusing on a landmark U.S. court ruling against EPA restrictions, a speculative price rally in China, a deadly DCM-related industrial accident in India, and a structurally weak long-term demand outlook shaped by regulation and Asian market dynamics. Buyers can source Methylene Chloride (DCM) from our supply network.
U.S. Regulatory Reversal: Fifth Circuit Vacates EPA’s Risk-Management Rule
The most significant regulatory news this month is the U.S. Court of Appeals for the Fifth Circuit’s decision on September 15, 2026, to vacate the EPA’s 2024 methylene chloride rule under Section 6 of the Toxic Substances Control Act (TSCA).
The 2024 rule had banned all consumer uses of methylene chloride and imposed strict workplace controls on the few remaining commercial and industrial applications. In East Fork Enterprises v. EPA, the court ruled that the EPA’s “whole chemical” approach—aggregating risks across all uses to justify broad restrictions—was “contrary to law, arbitrary and capricious, and unsupported by substantial evidence.” The court held that TSCA requires the EPA to assess unreasonable risk on an individual condition-of-use basis, and that the agency improperly assumed workers do not use personal protective equipment (PPE) where such use is common and foreseeable. The ruling is the first appellate decision on a risk-management rule issued under TSCA’s 2016 amendments.
The American Chemistry Council (ACC) welcomed the decision, stating it provides “greater transparency, stakeholder engagement, and regulatory certainty” for future TSCA implementation. The matter has been remanded to the EPA, and regulated entities are now monitoring how the agency will respond to the court’s rebuke. Separately, a coalition of environmental groups is continuing to petition the FDA to revoke approvals for methylene chloride as a food additive and coloring agent.
Chinese Market: Price Surge Driven by Geopolitical Conflict and Supply Contraction
In China, dichloromethane prices have experienced a sharp rally in October. As of October 13, the mixed price for premium-grade material in Shandong reached RMB 3,295 per ton, up 12.55% week-on-week and 88.29% year-on-year. The cumulative increase over 60 days from the August 24 low of RMB 2,395/ton was 69.41%. By October 19, the price had edged higher to RMB 3,287.50/ton, representing a 10.60% gain in 10 days and a 67.52% rise over 60 days.
The rally is attributed to geopolitical tensions pushing up crude oil prices, which in turn lifted the entire chlor-alkali chain. Industry data show the operating rate for methane chloride units fell to just 34.45%, while inventory dropped 50.38% year-on-year. On the supply side, several major producers—including Shandong Jinling’s Dongying plant (offline since August 22) and Luxi Chemical (low-load operation)—have curtailed output, tightening spot availability. Despite the price surge, co-production economics remain under pressure: the methane chloride unit producing DCM has recorded an average loss of RMB 195 per ton since September.
Industrial Safety: Fatal Reactor Explosion in India Causes MDC Gas Leak
On the evening of October 16–17, 2026, a 15-kilolitre reactor exploded during a hydrogenation process at a pharmaceutical manufacturing unit in Bharuch district, Gujarat, India. At least five workers were killed and five to six others injured. The blast also caused a leak of methylene dichloride (MDC) gas, adding a toxic exposure risk to the incident. The accident underscores the acute industrial-safety hazards associated with DCM handling, particularly in pharmaceutical and fine-chemical operations where the solvent remains difficult to substitute.
Long-Term Market Outlook: Flat Growth and Structural Shift
Despite the recent price volatility, the long-term demand trajectory for dichloromethane remains weak. A January 2026 market report projects the global DCM market to reach USD 434 million by 2032, with a CAGR of –0.4% during 2026–2032—essentially flat to slightly declining. Europe and China each account for roughly 30% of global market share, with China’s 2026 consumption of 271,000 tons representing 47% of the Asia-Pacific total, more than double that of second-place India (112,000 tons).
The structural story is one of regulatory-driven demand destruction in Western markets offset by continued pharmaceutical and specialty-chemical demand in Asia. China’s export channels have become a critical pressure-relief valve: the country exported 213,000 tons of DCM in 2025, up 40.9% year-on-year and a record high, with Turkey, Vietnam, Brazil, Nigeria, and South Korea collectively accounting for 43.5% of those exports. China’s production capacity represents approximately 48% of the global total.
